TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial and operating results for the first quarter 2009. The Company reported a net loss of $17.5 million, or $0.22 per share (basic and diluted), for the first quarter of 2009 compared with a net loss of $11.6 million, or $0.15 per share (basic and diluted), for the first quarter of 2008.
